Physician
Gastroenterology
Dr. Scott P. Henry, MD
|
|
Give Review
Dr. Scott P. Henry is an expert in the field of Gastroenterology. He graduated from New York Medical College. He has 3 awards "CMS Meaningful Use Stage 1 Certification", "Fellow (AGAF)" and "Fellow (FACG)". Scott P. Henry is a published MD. He has 46 publications published. The most current publication "Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys." Scott Henry accepts all Medicare patients.
Publications
- Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
- Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
- Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Develo...
- Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
- Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum.
- Considerations for assessment of reproductive and developmental toxicity of oligonucleotide-based therapeutics.
- Pharmacology of a central nervous System delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates.
- Local and Systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.
- Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies.
- Increased OMAR MA1 DV in PTSD.
- Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study.
- Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription...
- Antisense inhibition of coagulation factor XI prolongs APTT without increased Bleeding risk in cynomolgus monkeys.
- Antisense oligonucleotide therapy in diabetic retinopathy.
- Assessment of the effects of ISIS 2302, an anti-sense inhibitor of human ICAM-1, on cellular and humoral immunity in mice.
- CpG and Non-CpG oligodeoxynucleotides induce differential proinflammatory gene expression profiles in liver and peripheral blood leukocytes in mice.
- Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor...
- Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.
- Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits.
- Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
- Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species.
- Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization.
- Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.
- Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide.
- Fomivirsen: clinical pharmacology and potential drug interactions.
- Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
- Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
- Potential therapeutic application of antisense oligonucleotides in the treatment of ocular Diseases.
- Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
- Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys.
- Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
- Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys.
- Inhibition of coagulation by a phosphorothioate oligonucleotide.
- Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.
- Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit.
- Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents.
- Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.
- Antisense oligonucleotide inhibitors for the treatment of Cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.
- Antisense oligonucleotide inhibitors for the treatment of Cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
- Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys.
- Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action.
- Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats.
- Toxicological properties of several novel oligonucleotide analogs in mice.
- Predictive dose-based estimation of Systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modific...
- Inhibiting C-reactive protein for the treatment of cardiovascular Disease: promising evidence from rodent models.
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
- Hemorrhoidectomy or Excision of Anal Tags
- Liver Biopsy
- View All
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
- Choice Plus POS II
- Assurant Health
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- Coventry Health America PPO
- EBS-RMSCO
- Fidelis Care HMO
- First Health (Coventry Health Care) PPO
- Gateway Health Plan
- Community Blue PPO
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medical Mutual of Ohio
- Medicare MCR
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- NGS CoreSource
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Universal American
- UPMC PPO
- UPMC Health Plan
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (AGAF)
- Fellow (FACG)
Education
-
North Shore-Long Island Jewish Health System -
New York Medical College
Drug Facts
| NPI NUMBER | 1871598565 | |
| NPPES Provider LastName | HENRY | |
| NPPES Provider FirstName | SCOTT | |
| NPPES Provider ZIPCode | 165071423 | |
| NPPES Provider State | PA | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 2570.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871598565 |
| Last Name Of The Provider | HENRY |
| First Name Of The Provider | SCOTT |
| View All |
Similar Doctors
|
|
Dr. David J. Levy, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vladislava Buntic, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vinod M. Patel, MD |
|
|
Dr. Dinesh C. Khera, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Y. Lin, MD |
|
|
Dr. Brian Y. Ng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert M. Schwartz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yasser Jamal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William H. Wismer, DO
This Doctor is OpenDoctor Recommended.
|